

# Vulva

## Protocol applies to invasive carcinomas of the vulva.

---

*Protocol revision date: January 2005  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition  
and FIGO 2001 Annual Report*

### Procedures

- **Cytology** (No Accompanying Checklist)
- **Incisional Biopsy** (No Accompanying Checklist)
- **Excisional Biopsy**
- **Vulvectomy (With or Without Removal of Other Organs and Tissues)**

### Author

Philip A. Branton, MD

Department of Pathology, Inova Fairfax Hospital, Fairfax, Virginia  
For the Members of the Cancer Committee, College of American Pathologists

**Previous contributors:** Edward J. Wilkinson, MD; Robert E. Scully, MD

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the "Surgical Pathology Cancer Case Summary (Checklist)" portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

## **Summary of Changes to Checklist(s)**

*Protocol revision date: January 2005*

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

## Surgical Pathology Cancer Case Summary (Checklist)

*Protocol revision date: January 2005  
Applies to invasive carcinomas only  
Based on AJCC/UICC TNM, 6<sup>th</sup> edition  
and FIGO 2001 Annual Report*

### VULVA: Excisional Biopsy, Resection

Patient name:

Surgical pathology number:

<b>Note: Check 1 response unless otherwise indicated.</b>
---

#### MACROSCOPIC

##### Specimen Type

- Local excision  
 Wide excision  
 Partial vulvectomy  
 Total vulvectomy  
 Radical vulvectomy  
 Other (specify): \_\_\_\_\_  
 Not specified

##### Lymphadenectomy

- Not applicable  
 Sentinel lymph node biopsy  
 Inguinal-femoral nodes  
 Pelvic nodes  
 Other (specify): \_\_\_\_\_

##### Tumor Site (check all that apply)

- Right vulva  
     \*  Labia major  
     \*  Labia minor  
 Left vulva  
     \*  Labia major  
     \*  Labia minor  
 Clitoris  
 Other (specify): \_\_\_\_\_  
 Not specified

4           \* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Tumor Size**

Greatest dimension: \_\_\_ cm

\*Additional dimensions: \_\_\_ x \_\_\_ cm

\_\_\_ Cannot be determined (see Comment)

**MICROSCOPIC****Histologic Type (check all that apply)**

\_\_\_ Squamous cell carcinoma

\* \_\_\_ Keratinizing

\* \_\_\_ Non keratinizing

\* \_\_\_ Basaloid

\* \_\_\_ Warty (condylomatous)

\* \_\_\_ Other (specify): \_\_\_\_\_

\_\_\_ Verrucous carcinoma

\_\_\_ Adenocarcinoma

\* \_\_\_ Carcinoma resembling breast carcinoma

\* \_\_\_ Eccrine carcinoma

\* \_\_\_ Other (specify): \_\_\_\_\_

\_\_\_ Paget disease

\_\_\_ Other (specify): \_\_\_\_\_

\_\_\_ Carcinoma, type cannot be determined

**Histologic Grade**

\_\_\_ Not applicable

\_\_\_ GX: Cannot be assessed

\_\_\_ G1: Well differentiated

\_\_\_ G2: Moderately differentiated

\_\_\_ G3: Poorly differentiated

\_\_\_ G4: Undifferentiated

\_\_\_ Other (specify): \_\_\_\_\_

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Pathologic Staging (pTNM [FIGO])**

Primary Tumor (pT)

- pTX [--]: Cannot be assessed
- pT0 [--]: No evidence of primary tumor
- pTis [0]: Carcinoma in situ
- pT1 [I]: Tumor confined to vulva or vulva and perineum, 2 cm or less in greatest dimension
- pT1a [IA]: Tumor confined to vulva or vulva and perineum, 2 cm or less in greatest dimension, and with stromal invasion no more than 1 mm
- pT1b [IB]: Tumor confined to vulva or vulva and perineum, 2 cm or less in greatest dimension, and with stromal invasion greater than 1 mm
- pT2 [II]: Tumor confined to vulva or vulva and perineum greater than 2 cm in greatest dimension
- pT3 [III]: Tumor of any size with contiguous spread to the lower urethra and/or vagina or anus
- pT4 [IVA]: Tumor invades any of the following: upper urethra, bladder mucosa, rectal mucosa, or is fixed to pubic bone

Regional Lymph Nodes (pN)

- pNX: Cannot be assessed
  - pN0: No regional lymph node metastasis
  - pN1 [III]: Unilateral regional lymph node metastasis (pT1-pT3)
  - pN1 [IVA]: Unilateral regional lymph node metastasis (pT4)
  - pN1 [IVB]: Unilateral regional lymph node metastasis (pT1-pT4, pM1)
  - pN2 [IVA]: Bilateral regional lymph node metastasis (pT1-pT4)
  - pN2 [IVB]: Bilateral regional lymph node metastasis (pT1-pT4, pM1)
- Specify: Number examined:
- Number involved:

Distant Metastasis (pM)

- pMX: Cannot be assessed
  - pM1 [IVB]: Distant metastasis
- \*Specify site(s), if known: \_\_\_\_\_

**Depth of Invasion**

- Specify:  mm
- Cannot be determined (see Comment)

**\*Tumor Border**

- \*  Pushing
- \*  Infiltrating

6 \* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Margins (check all that apply)**

- Cannot be assessed
- Uninvolved by invasive carcinoma  
 Distance of invasive carcinoma from closest margin: \_\_\_ mm  
 Specify margin, if possible: \_\_\_\_\_
- Carcinoma in situ absent at margin
- Carcinoma in situ present at margin
- Involved by invasive carcinoma  
 Specify margin(s): \_\_\_\_\_

**\*Venous/Lymphatic (Large/Small Vessel) Invasion (V/L)**

- \*  Absent
- \*  Present
- \*  Indeterminate

**\*Additional Pathologic Findings (check all that apply)**

- \*  None identified
- \*  Dysplasia
- \*  Condyloma accuminatum
- \*  Vulvar intraepithelial neoplasia 3 (VIN3: severe dysplasia/carcinoma in situ)
- \*  Other (specify): \_\_\_\_\_

**\*Comment(s)**

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.